Literature DB >> 26172134

Intrahepatic cholangiocarcinoma: expert consensus statement.

Sharon M Weber1, Dario Ribero2, Eileen M O'Reilly3, Norihiro Kokudo4, Masaru Miyazaki5, Timothy M Pawlik6.   

Abstract

An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists met on 15 January 2014 to review current evidence on the management of intrahepatic cholangiocarcinoma (ICC) in order to establish practice guidelines and to agree on consensus statements. The treatment of ICC requires a coordinated, multidisciplinary approach to optimize survival. Biopsy is not necessary if the surgeon suspects ICC and is planning curative resection, although biopsy should be obtained before systemic or locoregional therapies are initiated. Assessment of resectability is best accomplished using cross-sectional imaging [computed tomography (CT) or magnetic resonance imaging (MRI)], but the role of positron emission tomography (PET) is unclear. Resectability in ICC is defined by the ability to completely remove the disease while leaving an adequate liver remnant. Extrahepatic disease, multiple bilobar or multicentric tumours, and lymph node metastases beyond the primary echelon are contraindications to resection. Regional lymphadenectomy should be considered a standard part of surgical therapy. In patients with high-risk features, the routine use of diagnostic laparoscopy is recommended. The preoperative diagnosis of combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC) by imaging studies is extremely difficult. Surgical resection remains the mainstay of treatment, but survival is worse than in HCC alone. There are no adequately powered, randomized Phase III trials that can provide definitive recommendations for adjuvant therapy for ICC. Patients with high-risk features (lymphovascular invasion, multicentricity or satellitosis, large tumours) should be encouraged to enrol in clinical trials and to consider adjuvant therapy. Cisplatin plus gemcitabine represents the standard-of-care, front-line systemic therapy for metastatic ICC. Genomic analyses of biliary cancers support the development of targeted therapeutic interventions.
© 2015 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2015        PMID: 26172134      PMCID: PMC4527852          DOI: 10.1111/hpb.12441

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  78 in total

Review 1.  Endoscopic ultrasound staging of cholangiocarcinoma.

Authors:  Michael J Levy; Julie K Heimbach; Gregory J Gores
Journal:  Curr Opin Gastroenterol       Date:  2012-05       Impact factor: 3.287

2.  Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma.

Authors:  T Todoroki; K Ohara; T Kawamoto; N Koike; S Yoshida; H Kashiwagi; M Otsuka; K Fukao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-02-01       Impact factor: 7.038

3.  AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group.

Authors:  Olivier Farges; David Fuks; Yves-Patrice Le Treut; Daniel Azoulay; Alexis Laurent; Philippe Bachellier; Gennaro Nuzzo; Jacques Belghiti; François René Pruvot; Jean Marc Regimbeau
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

4.  Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome.

Authors:  William R Jarnagin; David S Klimstra; Michael Hezel; Mithat Gonen; Yuman Fong; Kevin Roggin; Karina Cymes; Ronald P DeMatteo; Michael D'Angelica; Leslie H Blumgart; Bhuvanesh Singh
Journal:  J Clin Oncol       Date:  2006-03-01       Impact factor: 44.544

5.  Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI.

Authors:  Kathryn J Fowler; Arman Sheybani; Rex A Parker; Sean Doherty; Elizabeth M Brunt; William C Chapman; Christine O Menias
Journal:  AJR Am J Roentgenol       Date:  2013-08       Impact factor: 3.959

6.  Peripheral cholangiocarcinoma: presentation, diagnosis, pathology and management.

Authors:  Z E El Rassi; C Partensky; J Y Scoazec; L Henry; C Lombard-Bohas; G Maddern
Journal:  Eur J Surg Oncol       Date:  1999-08       Impact factor: 4.424

Review 7.  Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy.

Authors:  Melanie B Thomas
Journal:  Crit Rev Oncol Hematol       Date:  2007-01       Impact factor: 6.312

8.  Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes.

Authors:  Taro Aoba; Tomoki Ebata; Yukihiro Yokoyama; Tsuyoshi Igami; Gen Sugawara; Yu Takahashi; Yuji Nimura; Masato Nagino
Journal:  Ann Surg       Date:  2013-04       Impact factor: 12.969

9.  Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies.

Authors:  William R Jarnagin; Leyo Ruo; Sarah A Little; David Klimstra; Michael D'Angelica; Ronald P DeMatteo; Raquel Wagman; Leslie H Blumgart; Yuman Fong
Journal:  Cancer       Date:  2003-10-15       Impact factor: 6.860

Review 10.  The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan.

Authors: 
Journal:  Jpn J Surg       Date:  1989-01
View more
  113 in total

1.  Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis.

Authors:  John R Bergquist; Tommy Ivanics; Curtis B Storlie; Ryan T Groeschl; May C Tee; Elizabeth B Habermann; Rory L Smoot; Michael L Kendrick; Michael B Farnell; Lewis R Roberts; Gregory J Gores; David M Nagorney; Mark J Truty
Journal:  J Surg Oncol       Date:  2016-07-20       Impact factor: 3.454

2.  Pre-operative Sarcopenia Identifies Patients at Risk for Poor Survival After Resection of Biliary Tract Cancers.

Authors:  Jeffery Chakedis; Gaya Spolverato; Eliza W Beal; Ingrid Woelfel; Fabio Bagante; Katiuscha Merath; Steven H Sun; Aaron Chafitz; Jason Galo; Mary Dillhoff; Jordan Cloyd; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2018-05-31       Impact factor: 3.452

Review 3.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

4.  Facility Type is Associated with Margin Status and Overall Survival of Patients with Resected Intrahepatic Cholangiocarcinoma.

Authors:  Grace C Lee; T Clark Gamblin; Zhi Ven Fong; Cristina R Ferrone; Lipika Goyal; Keith D Lillemoe; Lawrence S Blaszkowsky; Kenneth K Tanabe; Motaz Qadan
Journal:  Ann Surg Oncol       Date:  2019-07-31       Impact factor: 5.344

5.  Consensus conference on intrahepatic cholangiocarcinoma.

Authors:  Ghassan K Abou-Alfa; Jean-François Geschwind; Michael Choti; Michael I d'Angelica
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

6.  Prognostic impacts of postoperative complications in patients with intrahepatic cholangiocarcinoma after curative operations.

Authors:  Tatsunori Miyata; Yo-Ichi Yamashita; Takanobu Yamao; Naoki Umezaki; Masayo Tsukamoto; Yuki Kitano; Kensuke Yamamura; Kota Arima; Takayoshi Kaida; Shigeki Nakagawa; Katsunori Imai; Daisuke Hashimoto; Akira Chikamoto; Takatoshi Ishiko; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2017-02-15       Impact factor: 3.402

7.  Ablative therapies for intrahepatic cholangiocarcinoma.

Authors:  Antonio Giorgio; Pietro Gatti; Paolo Matteucci; Valentina Giorgio
Journal:  Hepatobiliary Surg Nutr       Date:  2018-06       Impact factor: 7.293

8.  Oncologic Impact of Lymph Node Dissection for Intrahepatic Cholangiocarcinoma: a Propensity Score-Matched Study.

Authors:  Sung Hyun Kim; Dai Hoon Han; Gi Hong Choi; Jin Sub Choi; Kyung Sik Kim
Journal:  J Gastrointest Surg       Date:  2018-08-15       Impact factor: 3.452

Review 9.  Surgical options for intrahepatic cholangiocarcinoma.

Authors:  Kui Wang; Han Zhang; Yong Xia; Jian Liu; Feng Shen
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

10.  Genomic profiling of multifocal intrahepatic cholangiocarcinoma reveals intraindividual concordance of genetic alterations.

Authors:  Sung Hwan Lee; Eve B Simoneau; Tatiana Karpinets; P Andrew Futreal; Jianjun Zhang; Milind Javle; Jianhua Zhang; Jean-Nicolas Vauthey; Ju-Seog Lee; Jeannelyn S Estrella; Yun Shin Chun
Journal:  Carcinogenesis       Date:  2021-04-17       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.